Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977+Ribavirin for 12 Weeks in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection.
Conditions
Interventions
SOF
RBV
+2 more
Locations
77
Austria
Medizinische Universitat Graz
Graz, Austria
Medizinische Universitat Wien
Vienna, Austria
Wilhelminenspital
Vienna, Austria
West Tallinn Central Hospital
Tallinn, Estonia
Tartu University Hospital
Tartu, Estonia
CHRU de Lille, Hopital Claude Huriez
CHRU Lille, France
Start Date
September 1, 2012
Primary Completion Date
October 1, 2013
Completion Date
January 1, 2014
Last Updated
October 9, 2014
NCT06953479
NCT03135886
NCT05968573
NCT05042544
NCT05870969
NCT05361603
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions